Cadila Health Care v. Cadila Pharmaceuticals: the stricter test of deceptive similarity for medicinal products

The facts in brief

The dispute was, in a sense, a family quarrel. Both litigants traced their lineage to the erstwhile Cadila group. After that group was reorganised, two separate enterprises emerged, each carrying the Cadila name forward — the appellant, Cadila Health Care Ltd., and the respondent, Cadila Pharmaceuticals Ltd.

The appellant marketed an anti-malarial drug under the name "Falcigo." The drug contained artesunate and was used in the treatment of cerebral malaria — the falciparum strain of the disease, from which the brand name was evidently derived. The respondent subsequently launched its own drug for the same ailment under the name "Falcitab."

To the eye and the ear, the two names share a common opening: "Falci-." The appellant contended that the respondent's "Falcitab" was deceptively similar to its own "Falcigo," and sought to restrain the respondent from using it. Both products were directed at the same clinical condition, which sharpened the appellant's concern that a confused purchaser, dispenser or patient might receive one drug while intending the other.

The questions

The matter reached the Supreme Court as a passing-off dispute, and the central legal question was deceptively simple to state and difficult to apply: how is "deceptive similarity" to be judged between two competing marks?

The deeper question, and the one that gives the decision its lasting importance, was whether the ordinary yardstick of deceptive similarity should be applied in the same way when the competing goods are medicines. Pharmaceutical products are not interchangeable consumer items; a mistake in identity is not merely a commercial inconvenience but a potential threat to health and life. The Court therefore had to decide whether the standard of comparison should be relaxed or tightened where drugs are concerned, and what factors a court must weigh in reaching its conclusion.

What the Court held

The three-judge bench — B.N. Kirpal, J., Doraiswamy Raju, J. and Brijesh Kumar, J. — laid down the authoritative test for deceptive similarity in passing-off actions and held that a stricter standard governs medicinal and pharmaceutical products.

The reasoning rested on the consequences of error. Confusion between two drugs is not like confusion between two soaps or two biscuits; it can be fatal. Where the price of a mistake is a danger to public health, the Court held, the law cannot afford to be relaxed about even a modest degree of resemblance. Phonetic and structural similarity therefore carry greater weight in this context than they might in a dispute over ordinary articles of commerce.

The Court was also unwilling to accept the familiar reassurances that are sometimes offered to dispel the risk of confusion in the pharmaceutical trade — that purchasers of medicines exercise special care, or that the intervention of a prescribing physician and a dispensing pharmacist will catch any slip. In Indian conditions, the Court reasoned, those assumptions are unsafe. Varying levels of literacy, the realities of dispensing practice, and the proliferation of look-alike and sound-alike drug names mean that the chain between prescription and consumption cannot be trusted to neutralise a confusingly similar mark.

Having established the stricter approach, the Court set out the non-exhaustive list of factors relevant to the question of deceptive similarity:

• the nature of the marks, that is, whether the marks are word marks, label marks or composite marks;
• the degree of resemblance between the marks, phonetic, visual and conceptual;
• the nature of the goods in respect of which the marks are used;
• the similarity in the nature, character and performance of the goods of the rival traders;
• the class of purchasers who are likely to buy the goods, their education and intelligence and the degree of care they are likely to exercise;
• the mode of purchasing the goods or placing orders for them; and
• any other surrounding circumstances relevant to the dispute.

On the dispute before it, the Court did not itself grant the appellant final relief. It declined to decide the ultimate question of whether "Falcitab" should be restrained, leaving that determination to be made at trial by the lower court. What the Supreme Court settled was the governing test; the application of that test to the Falcigo–Falcitab facts was left for the court below.

Analysis

The significance of the decision lies less in its outcome — which was, in effect, a remand on the merits — than in the framework it built. Two moves stand out.

The first is the carving out of a distinct, heightened standard for medicinal marks. Trademark law had long recognised that deceptive similarity is a question of overall impression rather than meticulous side-by-side comparison, and that the test is the imperfect recollection of an average consumer with ordinary memory. The Court's contribution was to insist that this general approach be calibrated to the stakes. Because the harm from confusion in the pharmaceutical field is qualitatively different — and potentially irreversible — the threshold of resemblance that will trigger relief is correspondingly lower. A degree of similarity that might be tolerated between two ordinary products will not be tolerated between two drugs.

The second move is the Court's refusal to rely on the architecture of the supply chain as a safeguard. There is a tempting line of argument that the involvement of trained intermediaries — doctors writing prescriptions, pharmacists filling them — supplies a buffer that makes brand confusion improbable. The Court rejected that comfort as ill-suited to Indian realities, pointing to literacy levels, dispensing practices and the sheer density of similar-sounding names. By locating its reasoning in the actual conditions of the Indian market rather than an idealised model of careful prescription and dispensation, the Court gave the stricter test a practical, evidentiary foundation.

The seven enumerated factors are deliberately non-exhaustive, and their structure is instructive. They move outward from the marks themselves — their nature and degree of resemblance — to the goods, then to the people who buy the goods and the manner in which they buy them, and finally to a residual category of surrounding circumstances. The list does not reduce the inquiry to a mechanical checklist; it disciplines it. A court must attend to each consideration, but the weight of each will shift with the facts, and in the medicinal context the resemblance factors are weighted upward by design.

It is also worth noting what the Court did not do. It did not pronounce on whether the appellant must ultimately succeed, and it resisted the temptation to resolve the factual contest itself. That restraint preserved the role of the trial court while ensuring that the trial would proceed under the correct legal standard — a division of labour that gives the judgment its enduring utility as a statement of principle rather than a one-off result.

Why it matters

For anyone litigating or advising on pharmaceutical brands in India, this decision is the starting point. It establishes that the deceptive-similarity inquiry for medicines is not the ordinary inquiry conducted with a little more caution; it is a stricter inquiry in which even a modest phonetic or structural overlap can be decisive. Drug manufacturers choosing a brand name cannot rely on the presence of a prescribing doctor or a dispensing chemist to absorb the risk of confusion, and they cannot assume that purchasers will scrutinise the packaging with care.

The seven-factor framework has become the standard vocabulary of passing-off analysis well beyond the pharmaceutical sector, supplying a structured method for assessing deceptive similarity across categories of goods. But its sharpest edge remains in the field for which it was forged: where the goods are medicines and the cost of confusion is measured in human health, the Court's instruction is that the law should err on the side of caution. The Falcigo–Falcitab dispute thus produced a test whose reach extends far beyond the two anti-malarials that occasioned it.

Related on Valkya

• Flipkart India v. Marc Enterprises: MARQ deceptively similar to MARC
• Emami v. Dabur (Cool King): trade-dress passing-off and the composite-imitation test
• Pernod Ricard v. Karanveer Singh Chhabra: 'Pride' is publici juris and the anti-dissection rule
• People Interactive v. Lalitha Rani: Shaadi.com is a well-known mark

Sources

• Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73; 2001 PTC 541 (SC); AIR 2001 SC 1952.
• Drishti Judiciary, "Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd."
• SCC Online Blog, coverage tagged "Cadila Healthcare."